-
Je něco špatně v tomto záznamu ?
Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists
SR. Williamson, R. Gadde, K. Trpkov, MS. Hirsch, JR. Srigley, VE. Reuter, L. Cheng, LP. Kunju, R. Barod, CG. Rogers, B. Delahunt, O. Hes, JN. Eble, M. Zhou, JK. McKenney, G. Martignoni, S. Fleming, DJ. Grignon, H. Moch, NS. Gupta,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- biopsie MeSH
- diagnostické techniky molekulární MeSH
- diferenciální diagnóza MeSH
- imunohistochemie MeSH
- karcinom z renálních buněk chemie genetika patologie MeSH
- keratin-7 analýza MeSH
- lidé MeSH
- mitotický index MeSH
- nádorové biomarkery analýza genetika MeSH
- nádory ledvin chemie genetika patologie MeSH
- oxyfilní adenom chemie genetika patologie MeSH
- patologové * MeSH
- prediktivní hodnota testů MeSH
- prognóza MeSH
- proliferace buněk MeSH
- průzkumy zdravotní péče MeSH
- urologové * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Renal oncocytoma and chromophobe renal cell carcinoma have been long recognized as distinct tumors; however, it remains unknown if uniform diagnostic criteria are used to distinguish these tumor types in practice. A survey was distributed to urologic pathologists regarding oncocytic tumors. Responses were received from 17 of 26 invitees. Histologically, more than 1 mitotic figure was regarded as most worrisome (n=10) or incompatible (n=6) with oncocytoma diagnosis. Interpretation of focal nuclear wrinkling, focal perinuclear clearing, and multinucleation depended on extent and did not necessarily exclude oncocytoma if minor. Staining techniques most commonly used included the following: cytokeratin 7 (94%), KIT (71%), vimentin (65%), colloidal iron (59%), CD10 (53%), and AMACR (41%). Rare cytokeratin 7-positive cells (≤5%) were regarded as most supportive of oncocytoma, although an extent excluding oncocytoma was not universal. Multiple chromosomal losses were most strongly supportive for chromophobe renal cell carcinoma diagnosis (65%). Less certainty was reported for chromosomal gain or a single loss. For tumors with mixed or inconclusive features, many participants use an intermediate diagnostic category (82%) that does not label the tumor as unequivocally benign or malignant, typically "oncocytic neoplasm" or "tumor" with comment. The term "hybrid tumor" was used variably in several scenarios. A slight majority (65%) report outright diagnosis of oncocytoma in needle biopsies. The morphologic, immunohistochemical, and genetic characteristics that define oncocytic renal tumors remain incompletely understood. Further studies correlating genetics, behavior, and histology are needed to define which tumors truly warrant classification as carcinomas for patient counseling and follow-up strategies.
Department of Pathology and Diagnostics University of Verona Verona 37134 Italy
Department of Pathology and Laboratory Medicine Detroit MI 48202 United States
Department of Pathology and Molecular Medicine McMaster University Hamilton Ontario L5M 2N1 Canada
Department of Pathology Memorial Sloan Kettering Cancer Center New York NY 10065 United States
Department of Pathology New York University Medical Center New York NY 10016 United States
Department of Pathology Pederzoli Hospital Peschiera del Garda 37014 Italy
Department of Pathology University Hospital Zurich Zurich CH 8091 Switzerland
Department of Pathology University of Michigan School of Medicine Ann Arbor MI 48109 United States
Department of Pathology Wayne State University School of Medicine Detroit MI 48202 United States
Henry Ford Cancer Institute Henry Ford Health System Detroit MI 48202 United States
Robert J Tomsich Pathology and Laboratory Medicine Institute Cleveland Clinic Cleveland OH 44195 USA
Vattikutti Urology Institute Henry Ford Health System Detroit MI 48202 USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17030952
- 003
- CZ-PrNML
- 005
- 20201019102049.0
- 007
- ta
- 008
- 171025s2017 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.humpath.2017.03.004 $2 doi
- 035 __
- $a (PubMed)28315424
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Williamson, Sean R $u Department of Pathology and Laboratory Medicine, Detroit, MI, 48202, United States; Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, 48202, United States; Department of Pathology, Wayne State University School of Medicine, Detroit, MI, 48202, United States. Electronic address: seanwill@temple.edu.
- 245 10
- $a Diagnostic criteria for oncocytic renal neoplasms: a survey of urologic pathologists / $c SR. Williamson, R. Gadde, K. Trpkov, MS. Hirsch, JR. Srigley, VE. Reuter, L. Cheng, LP. Kunju, R. Barod, CG. Rogers, B. Delahunt, O. Hes, JN. Eble, M. Zhou, JK. McKenney, G. Martignoni, S. Fleming, DJ. Grignon, H. Moch, NS. Gupta,
- 520 9_
- $a Renal oncocytoma and chromophobe renal cell carcinoma have been long recognized as distinct tumors; however, it remains unknown if uniform diagnostic criteria are used to distinguish these tumor types in practice. A survey was distributed to urologic pathologists regarding oncocytic tumors. Responses were received from 17 of 26 invitees. Histologically, more than 1 mitotic figure was regarded as most worrisome (n=10) or incompatible (n=6) with oncocytoma diagnosis. Interpretation of focal nuclear wrinkling, focal perinuclear clearing, and multinucleation depended on extent and did not necessarily exclude oncocytoma if minor. Staining techniques most commonly used included the following: cytokeratin 7 (94%), KIT (71%), vimentin (65%), colloidal iron (59%), CD10 (53%), and AMACR (41%). Rare cytokeratin 7-positive cells (≤5%) were regarded as most supportive of oncocytoma, although an extent excluding oncocytoma was not universal. Multiple chromosomal losses were most strongly supportive for chromophobe renal cell carcinoma diagnosis (65%). Less certainty was reported for chromosomal gain or a single loss. For tumors with mixed or inconclusive features, many participants use an intermediate diagnostic category (82%) that does not label the tumor as unequivocally benign or malignant, typically "oncocytic neoplasm" or "tumor" with comment. The term "hybrid tumor" was used variably in several scenarios. A slight majority (65%) report outright diagnosis of oncocytoma in needle biopsies. The morphologic, immunohistochemical, and genetic characteristics that define oncocytic renal tumors remain incompletely understood. Further studies correlating genetics, behavior, and histology are needed to define which tumors truly warrant classification as carcinomas for patient counseling and follow-up strategies.
- 650 _2
- $a oxyfilní adenom $x chemie $x genetika $x patologie $7 D018249
- 650 _2
- $a nádorové biomarkery $x analýza $x genetika $7 D014408
- 650 _2
- $a biopsie $7 D001706
- 650 _2
- $a karcinom z renálních buněk $x chemie $x genetika $x patologie $7 D002292
- 650 _2
- $a proliferace buněk $7 D049109
- 650 _2
- $a diferenciální diagnóza $7 D003937
- 650 _2
- $a průzkumy zdravotní péče $7 D019538
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a keratin-7 $x analýza $7 D053552
- 650 _2
- $a nádory ledvin $x chemie $x genetika $x patologie $7 D007680
- 650 _2
- $a mitotický index $7 D008940
- 650 _2
- $a diagnostické techniky molekulární $7 D025202
- 650 12
- $a patologové $7 D000072142
- 650 _2
- $a prediktivní hodnota testů $7 D011237
- 650 _2
- $a prognóza $7 D011379
- 650 12
- $a urologové $7 D000072178
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Gadde, Ramya $u Department of Pathology and Laboratory Medicine, Detroit, MI, 48202, United States.
- 700 1_
- $a Trpkov, Kiril $u Department of Pathology and Laboratory Medicine, Calgary Laboratory Service and University of Calgary, Calgary, Alberta, T2V 1P9, Canada.
- 700 1_
- $a Hirsch, Michelle S $u Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 02115, United States.
- 700 1_
- $a Srigley, John R. $7 xx0252922 $u Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, L5M 2N1, Canada.
- 700 1_
- $a Reuter, Victor E $u Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.
- 700 1_
- $a Cheng, Liang $u Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, 46202, United States.
- 700 1_
- $a Kunju, L Priya $u Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, 48109, United States.
- 700 1_
- $a Barod, Ravi $u Vattikutti Urology Institute, Henry Ford Health System, Detroit, MI, 48202, USA.
- 700 1_
- $a Rogers, Craig G $u Vattikutti Urology Institute, Henry Ford Health System, Detroit, MI, 48202, USA.
- 700 1_
- $a Delahunt, Brett $u Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago - Wellington, Wellington, 6242, New Zealand.
- 700 1_
- $a Hes, Ondrej $u Department of Pathology, Charles University in Prague, Faculty of Medicine in Plzeň, Pilsen, 304 60, Czech Republic.
- 700 1_
- $a Eble, John N $u Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, 46202, United States.
- 700 1_
- $a Zhou, Ming $u Department of Pathology, New York University Medical Center, New York, NY, 10016, United States.
- 700 1_
- $a McKenney, Jesse K $u Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, 44195, USA.
- 700 1_
- $a Martignoni, Guido $u Department of Pathology and Diagnostics, University of Verona, Verona, 37134, Italy; Department of Pathology, Pederzoli Hospital, Peschiera del Garda, 37014, Italy.
- 700 1_
- $a Fleming, Stewart $u Department of Cellular and Molecular Pathology, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, United Kingdom.
- 700 1_
- $a Grignon, David J., $d -2020 $7 xx0252915 $u Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, IN, 46202, United States.
- 700 1_
- $a Moch, Holger $u Department of Pathology, University Hospital Zurich, Zurich, CH-8091, Switzerland.
- 700 1_
- $a Gupta, Nilesh S $u Department of Pathology and Laboratory Medicine, Detroit, MI, 48202, United States; Henry Ford Cancer Institute, Henry Ford Health System, Detroit, MI, 48202, United States.
- 773 0_
- $w MED00002080 $t Human pathology $x 1532-8392 $g Roč. 63, č. - (2017), s. 149-156
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28315424 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20171025 $b ABA008
- 991 __
- $a 20201019102023 $b ABA008
- 999 __
- $a ok $b bmc $g 1254545 $s 991979
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2017 $b 63 $c - $d 149-156 $e 20170314 $i 1532-8392 $m Human pathology $n Hum Pathol $x MED00002080
- LZP __
- $a Pubmed-20171025
